乐普医疗(300003.SZ):一季度扣非净利预增30%-60%
格隆汇 1 月 30日丨乐普医疗(300003.SZ)披露2021年第一季度业绩预告,预计归属于上市公司股东的扣除非经常性损益的净利润4.88亿元–6.01亿元,同比增长30%-60%。
报告期首月运营,随着国家组织冠脉支架集中带量采购的实施,传统支架业务显著下降,但可降解支架、药物球囊、切割球囊都实现了非常显著的增长,传统支架集采对公司支架业务的冲击正在逐步减少;体外诊断业务及人工智能业务呈现很好的增长态势;药品业务,经过2020年整年集采期运营,恢复了过去较高速增长的态势。综合上述主营业务所带来的归属于上市公司股东的扣除非经常性损益的净利润预计较上年同期有30%至60%之间的增长。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.